TGF-β1 as possible link between loss of bone mineral density and chronic inflammation

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Ehnert, Sabrina ^a   Baur, Johannes ^a   Schmitt, Andreas ^a   Neumaier, Markus ^a   Lucke, Martin ^a   Dooley, Steven ^b   Vester, Helen ^a   Wildemann, Britt ^c   Stöckle, Ulrich ^a   Nussler, Andreas K ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; BONE SIALOPROTEIN; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; OSTEOPROTEGERIN; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA1; 1,3 DIOXOLANE DERIVATIVE; 4 (5 BENZO(1,3)DIOXOL 5 YL 4 PYRIDIN 2 YL 1H IMIDAZOL 2 YL)BENZAMIDE; 4-(5-BENZO(1,3)DIOXOL-5-YL-4-PYRIDIN-2-YL-1H-IMIDAZOL-2-YL)BENZAMIDE; BENZAMIDE DERIVATIVE; BMP2 PROTEIN, HUMAN; BMP7 PROTEIN, HUMAN; OSTEOGENIC PROTEIN 1; PROTEIN SERINE THREONINE KINASE; SMAD PROTEIN; TGF BETA TYPE I RECEPTOR; TGF-BETA TYPE I RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

AGED; ARTICLE; BONE DENSITY; CELL ACTIVITY; CELL PROLIFERATION; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; NUCLEOTIDE SEQUENCE; OSTEOBLAST; OSTEOCLAST; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TOTAL HIP PROSTHESIS; BLOOD; CELL CULTURE; CHRONIC DISEASE; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATION; METABOLISM; OSTEOLYSIS; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME;

AGED; ALKALINE PHOSPHATASE; BENZAMIDES; BONE DENSITY; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 7; BONE RESORPTION; CELL PROLIFERATION; CELLS, CULTURED; CHRONIC DISEASE; DIOXOLES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; MALE; OSTEOBLASTS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RANK LIGAND; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMAD PROTEINS; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 78649503427     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014073     Document Type: Article

References (49)

1. Reddi AH (1998) Role of morphogenetic proteins in skeletal tissue engineering and regeneration. Nat Biotechnol 16: 247-252.
2. Bonewald LF, Dallas SL (1994) Role of active and latent transforming growth factor beta in bone formation. J Cell Biochem 55: 350-357.
3. Erlebacher A, Filvaroff EH, Ye JQ, Derynck R (1998) Osteoblastic responses to TGF-beta during bone remodeling. Mol Biol Cell 9: 1903-1918.
4. Robey PG, Young MF, Flanders KC, Roche NS, Kondaiah P, et al. (1987) Osteoblasts synthesize and respond to transforming growth factor-type beta (TGF-beta) in vitro. J Cell Biol 105: 457-463.
5. Pfeilschifter J, Bonewald L, Mundy GR (1990) Characterization of the latent transforming growth factor beta complex in bone. J Bone Miner Res 5: 49-58.
6. Noda M, Camilliere JJ (1989) In vivo stimulation of bone formation by transforming growth factor-beta. Endocrinology 124: 2991-2994.
7. Gressner AM, Weiskirchen R, Breitkopf K, Dooley S (2002) Roles of TGF-beta in hepatic fibrosis. Front Biosci 7: d793-807.
8. Kanzler S, Baumann M, Schirmacher P, Dries V, Bayer E, et al. (2001) Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta. J Viral Hepat 8: 430-437.
9. Border WA, Noble NA (1994) Transforming growth factor beta in tissue fibrosis. N Engl J Med 331: 1286-1292.
10. Fedulov AV, Ses TP, Gavrisheva NA, Rybakova MG, Vassilyeva JG, et al. (2005) Serum TGF-beta 1 and TNF-alpha levels and cardiac fibrosis in experimental chronic renal failure. Immunol Invest 34: 143-152.
11. Leask A (2007) TGFbeta, cardiac fibroblasts, and the fibrotic response. Cardiovasc Res 74: 207-212.
12. Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425: 577-584.
13. Shi Y, Massague J (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113: 685-700.
14. Piek E, Heldin CH, Ten Dijke P (1999) Specificity, diversity, and regulation in TGF-beta superfamily signaling. FASEB J 13: 2105-2124.
15. Miyazawa K, Shinozaki M, Hara T, Furuya T, Miyazono K (2002) Two major Smad pathways in TGF-beta superfamily signalling. Genes Cells 7: 1191-1204.
16. Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, et al. (2002) SB- 431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 62: 65-74.
17. Centrella M, Horowitz MC, Wozney JM, McCarthy TL (1994) Transforming growth factor-beta gene family members and bone. Endocr Rev 15: 27-39.
18. Schmidmaier G, Lucke M, Schwabe P, Raschke M, Haas NP, et al. (2006) Collective review: bioactive implants coated with poly(D,L-lactide) and growth factors IGF-I, TGF-beta1, or BMP-2 for stimulation of fracture healing. J Long Term Eff Med Implants 16: 61-69.
19. Wildemann B, Schmidmaier G, Brenner N, Huning M, Stange R, et al. (2004) Quantification, localization, and expression of IGF-I and TGF-beta1 during growth factor-stimulated fracture healing. Calcif Tissue Int 74: 388-397.
20. Dallas SL, Sivakumar P, Jones CJ, Chen Q, Peters DM, et al. (2005) Fibronectin regulates latent transforming growth factor-beta (TGF beta) by controlling matrix assembly of latent TGF beta-binding protein-1. J Biol Chem 280: 18871-18880.
21. Harris SE, Bonewald LF, Harris MA, Sabatini M, Dallas S, et al. (1994) Effects of transforming growth factor beta on bone nodule formation and expression of bone morphogenetic protein 2, osteocalcin, osteopontin, alkaline phosphatase, and type I collagen mRNA in long-term cultures of fetal rat calvarial osteoblasts. J Bone Miner Res 9: 855-863.
22. Ignotz RA, Massague J (1987) Cell adhesion protein receptors as targets for transforming growth factor-beta action. Cell 51: 189-197.
23. Lind M (1998) Growth factor stimulation of bone healing. Effects on osteoblasts, osteomies, and implants fixation. Acta Orthop Scand Suppl 283: 2-37.
24. Dieudonne SC, Foo P, van Zoelen EJ, Burger EH (1991) Inhibiting and stimulating effects of TGF-beta 1 on osteoclastic bone resorption in fetal mouse bone organ cultures. J Bone Miner Res 6: 479-487.
25. Hattersley G, Chambers TJ (1991) Effects of transforming growth factor beta 1 on the regulation of osteoclastic development and function. J Bone Miner Res 6: 165-172.
26. Lamberts SW, van den Beld AW, van der Lely AJ (1997) The endocrinology of aging. Science 278: 419-424.
27. Manolagas SC (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21: 115-137.
28. Rosen CJ (1994) Growth hormone, insulin-like growth factors, and the senescent skeleton: Ponce de Leon's Fountain revisited? J Cell Biochem 56: 348-356.
29. Wrana JL, Maeno M, Hawrylyshyn B, Yao KL, Domenicucci C, et al. (1988) Differential effects of transforming growth factor-beta on the synthesis of extracellular matrix proteins by normal fetal rat calvarial bone cell populations. J Cell Biol 106: 915-924.
30. Geiser AG, Zeng QQ, Sato M, Helvering LM, Hirano T, et al. (1998) Decreased bone mass and bone elasticity in mice lacking the transforming growth factorbeta1 gene. Bone 23: 87-93.
31. Joyce ME, Jingushi S, Bolander ME (1990) Transforming growth factor-beta in the regulation of fracture repair. Orthop Clin North Am 21: 199-209.
32. Rosen D, Miller SC, DeLeon E, Thompson AY, Bentz H, et al. (1994) Systemic administration of recombinant transforming growth factor beta 2 (rTGF-beta 2) stimulates parameters of cancellous bone formation in juvenile and adult rats. Bone 15: 355-359.
33. Erlebacher A, Derynck R (1996) Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype. J Cell Biol 132: 195-210.
34. Filvaroff E, Erlebacher A, Ye J, Gitelman SE, Lotz J, et al. (1999) Inhibition of TGF-beta receptor signaling in osteoblasts leads to decreased bone remodeling and increased trabecular bone mass. Development 126: 4267-4279.
35. Mohammad KS, Chen CG, Balooch G, Stebbins E, McKenna CR, et al. (2009) Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS One 4: e5275.
36. Lai CF, Cheng SL (2002) Signal transductions induced by bone morphogenetic protein-2 and transforming growth factor-beta in normal human osteoblastic cells. J Biol Chem 277: 15514-15522.
37. Rosier RN, O'Keefe RJ, Hicks DG (1998) The potential role of transforming growth factor beta in fracture healing. Clin Orthop Relat Res. pp S294-300.
38. Thirunavukkarasu K, Miles RR, Halladay DL, Yang X, Galvin RJ, et al. (2001) Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. J Biol Chem 276: 36241-36250.
39. Kaneda T, Nojima T, Nakagawa M, Ogasawara A, Kaneko H, et al. (2000) Endogenous production of TGF-beta is essential for osteoclastogenesis induced by a combination of receptor activator of NF-kappa B ligand and macrophagecolony- stimulating factor. J Immunol 165: 4254-4263.
40. Maeda S, Hayashi M, Komiya S, Imamura T, Miyazono K (2004) Endogenous TGF-beta signaling suppresses maturation of osteoblastic mesenchymal cells. EMBO J 23: 552-563.
41. Boden SD, Kang J, Sandhu H, Heller JG (2002) Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine (Phila Pa 1976) 27: 2662-2673.
42. Advincula MC, Rahemtulla FG, Advincula RC, Ada ET, Lemons JE, et al. (2006) Osteoblast adhesion and matrix mineralization on sol-gel-derived titanium oxide. Biomaterials 27: 2201-2212.
43. El-Amin SF, Botchwey E, Tuli R, Kofron MD, Mesfin A, et al. (2006) Human osteoblast cells: isolation, characterization, and growth on polymers for musculoskeletal tissue engineering. J Biomed Mater Res A 76: 439-449.
44. Harbers GM, Healy KE (2005) The effect of ligand type and density on osteoblast adhesion, proliferation, and matrix mineralization. J Biomed Mater Res A 75: 855-869.
45. Pfeilschifter J, Mundy GR (1987) Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones. Proc Natl Acad SciUS A 84: 2024-2028.
46. Robey PG, Termine JD (1985) Human bone cells in vitro. Calcif Tissue Int 37: 453-460.
47. Dooley S, Hamzavi J, Ciuclan L, Godoy P, Ilkavets I, et al. (2008) Hepatocytespecific Smad7 expression attenuates TGF-beta-mediated fibrogenesis and protects against liver damage. Gastroenterology 135: 642-659.
48. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, et al. (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112.
49. Wildemann B, Lubberstedt M, Haas NP, Raschke M, Schmidmaier G (2004) IGF-I and TGF-beta 1 incorporated in a poly(D,L-lactide) implant coating maintain their activity over long-term storage-cell culture studies on primary human osteoblast-like cells. Biomaterials 25: 3639-3644.